J&J Focuses on US Approval for Caplyta After Second Successful Bipolar Mania Trial

Johnson & Johnson (J&J) is aiming to secure US regulatory approval for its drug Caplyta in the treatment of bipolar mania. The company has moved toward the application process after receiving positive results from the drug's second clinical trial in this indication. According to a Reuters report, the second trial of Caplyta in bipolar mania treatment was successfully completed. This result strengthens the drug's chances of approval with the US Food and Drug Administration (FDA). J&J plans to submit a marketing application for Caplyta in the US using the data from this trial. The company's move is seen as part of its strategy to expand its position in the bipolar disorder treatment market. The second trial's success provides additional evidence supporting the drug's efficacy and safety profile. This development is being watched by investors for the growth potential in the company's drug portfolio. Not investment advice.

📊 GOOGL — Piyasa Yorumu

■ neutral · 30%

The given news headline concerns Johnson & Johnson's Caplyta drug and has no direct connection to GOOGL (Alphabet). Therefore, the news is not expected to have a meaningful short-term impact on GOOGL's price. Technical indicators are giving mixed signals: RSI at 49 is in neutral territory, MACD is slightly negative below the signal line, and the price is just below the SMA20 and above the SMA50. Despite a 1.47% rise in the last 24 hours, momentum is weak. The overall outlook points to a sideways trend.

RSI 14

49.0

MACD

0.03

24h Δ

1.47%

📊 JNJ — Piyasa Yorumu

▲ up · 62%

J&J's second successful trial of Caplyta in bipolar mania strengthens the drug's U.S. approval path, and the news flow is a mildly positive catalyst for the stock. The price at 280.77 is trading above the SMA20 (278.97) and SMA50 (274.58); the short-term trend is upward. RSI at 60 has not entered overbought territory, leaving limited upside room. Although MACD is slightly below the signal line (1.86 vs 2.05), it remains in positive territory; momentum is weak but not deteriorated. After a 2.5% rise over 24 hours, I see moderate potential for short-term continuation, but I keep confidence moderate due to the possibility that the news is already priced in.

RSI 14

60.3

MACD

1.86

24h Δ

2.50%

Canlı Grafikler